Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
Kyverna Therapeutics, Inc.
Market Cap
$377.23M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$376.10M
Net Profit Margin
-81.04%
TTM Avg
-157.37%
3Y Avg
-379.90%
5Y Avg
-317.33%
Market Cap
$377.17M
Net Profit Margin
-391.90%
TTM Avg
-78.17%
3Y Avg
-42.66%
5Y Avg
-429.16%
Market Cap
$379.14M
Net Profit Margin
-1392.61%
TTM Avg
-834.59%
3Y Avg
-416.33%
5Y Avg
-277.55%
Market Cap
$381.80M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$382.59M
Net Profit Margin
-7.41%
TTM Avg
-13.48%
3Y Avg
-12.88%
5Y Avg
-9.86%
Market Cap
$365.52M
Net Profit Margin
-1091.82%
TTM Avg
-436.37%
3Y Avg
-220.06%
5Y Avg
-1750.93%
Market Cap
$394.45M
Net Profit Margin
-112.58%
TTM Avg
-193.15%
3Y Avg
-231.74%
5Y Avg
-161.96%
Market Cap
$358.04M
Net Profit Margin
8.59%
TTM Avg
7.90%
3Y Avg
10.47%
5Y Avg
19.48%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | $377.23M | 0.00% | 0.00% | 0.00% | N/A |
| Canopy Growth Corporation (CGC)vs › | $376.10M | -81.04% | -157.37% | -379.90% | -317.33% |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $377.17M | -391.90% | -78.17% | -42.66% | -429.16% |
| YD Bio Limited Ordinary Shares (YDES)vs › | $379.14M | -1392.61% | -834.59% | -416.33% | -277.55% |
| Zura Bio Limited (ZURA)vs › | $381.80M | 0.00% | 0.00% | 0.00% | 0.00% |
| Orthofix Medical Inc. (OFIX)vs › | $382.59M | -7.41% | -13.48% | -12.88% | -9.86% |
| Opus Genetics, Inc. (IRD)vs › | $365.52M | -1091.82% | -436.37% | -220.06% | -1750.93% |
| REGENXBIO Inc. (RGNX)vs › | $394.45M | -112.58% | -193.15% | -231.74% | -161.96% |
| Embecta Corp. (EMBC)vs › | $358.04M | 8.59% | 7.90% | 10.47% | 19.48% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $357.58M | -5.49% | -11.37% | -410.78% | -2049.25% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | -3012.77% |
